Andrew J. Leishman

1.7k citations

34 papers · 1.3k indexed · h-index 18

Co-authors: Paul Garside Hilde Cheroutre Mitchell Kronenberg Allan McI. Mowat H. Robson MacDonald Laurent Gapin Myriam Capone Ed Palmer
Topics: Immune Cell Function and Interaction (16 papers)Immune Response and Inflammation (11 papers)Immunotherapy and Immune Responses (9 papers)
Cited by: Immunology Immunology and Allergy Oncology
Journals: Science Journal of Clinical Investigation The Journal of Experimental Medicine
Partner nations: United Kingdom United States Japan

In The Last Decade

Andrew J. Leishman

31 papers receiving 1.2k citations

Peers

Countries citing papers authored by Andrew J. Leishman

Since Specialization

Citations

This map shows the geographic impact of Andrew J. Leishman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew J. Leishman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew J. Leishman more than expected).

Fields of papers citing papers by Andrew J. Leishman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew J. Leishman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew J. Leishman. The network helps show where Andrew J. Leishman may publish in the future.

Co-authorship network of co-authors of Andrew J. Leishman

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew J. Leishman. A scholar is included among the top collaborators of Andrew J. Leishman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew J. Leishman. Andrew J. Leishman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 7004: CT7439 an oral first-in class selective CDK12 and 13 inhibitor and cyclin K degrader: Profiling activity and combination efficacy in an ovarian cancer model 2025 ·Cancer Research ·(unknown),(unknown),Stuart Thompson,(unknown),Andrew J. Leishman,Edward Ainscow	0
2	Abstract 3467: GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses 2023 ·Cancer Research ·Andrew J. Leishman,Wayne Paes,(unknown),(unknown),(unknown),Milos Aleksic,(unknown),(unknown),Kate Anderton,(unknown),(unknown),(unknown),Martin Quibell,(unknown)	0
3	Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies 2019 ·Journal for ImmunoTherapy of Cancer ·Stefanie Mullins,John P. Vasilakos,Katharina Deschler,Iwen F. Grigsby,(unknown),Julius Paul Pradeep John,Matthew J. Elder,John G. Swales,Elina Timosenko,Zachary A. Cooper,Simon J. Dovedi,Andrew J. Leishman,Nadia Luheshi,James Elvecrog,Ashenafi Y. Tilahun,Richard J. A. Goodwin,Ronald Herbst,Mark A. Tomai,Robert W. Wilkinson	137
4	Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade 2018 ·Frontiers in Immunology ·Robert W. Wilkinson,Andrew J. Leishman	22
5	CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML 2017 ·Blood ·Kristopher Clark,Edward Ainscow,(unknown),Stuart Thomson,Andrew J. Leishman,Elaine Sullivan,Simak Ali,R. Charles Coombes,Anthony G. M. Barrett,(unknown)	15
6	Intratracheal and oral administration of SM‐276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer 2012 ·International Journal of Cancer ·(unknown),Simon J. Dovedi,Masashi Murata,Hiroyuki Matsui,Andrew J. Leishman,John Bell,Douglas Ferguson,Simon P. Heaton,(unknown),Hideyuki Tomizawa,(unknown),Haruo Takaku,Robert W. Wilkinson,Hideyuki Harada	23
7	Biological characterization of a novel class of toll‐like receptor 7 agonists designed to have reduced systemic activity 2011 ·British Journal of Pharmacology ·Mark Biffen,Hiroyuki Matsui,(unknown),Andrew J. Leishman,(unknown),(unknown),(unknown),Ian Doyle,Hiroki Wada,(unknown),(unknown),Mikio Aoki,Hideyuki Tomizawa,(unknown),Haruo Takaku,Tom McInally,Clare Murray	30
8	Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141+XCR1+ dendritic cells 2011 ·Gene Therapy ·(unknown),Jonathan D. Silk,(unknown),T. J. Davies,Kathleen F. Nolan,Andrew J. Leishman,Lee Carpenter,Suzanne M. Watt,Vincenzo Cerundolo,Paul J. Fairchild	52
9	Biological Activity Of Novel TLR7 Ante-drug Agonists For The Treatment Of Allergic Diseases 2010 ·Mark Biffen,Hiroyuki Matsui,(unknown),(unknown),Ian Doyle,(unknown),Andrew J. Leishman,(unknown),(unknown),Hideyuki Tomizawa,Haruo Takaku,Clare Murray	2
10	Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity 2010 ·Expert Opinion on Investigational Drugs ·Andrew J. Leishman,Gary P. Sims,Matthew A. Sleeman,Martin Braddock	5
11	CpG-containing immunostimulatory DNA sequences elicit TNF-α–dependent toxicity in rodents but not in humans 2009 ·Journal of Clinical Investigation ·John D. Campbell,(unknown),Martyn Foster,Holger Kanzler,(unknown),(unknown),M. Ratcliffe,(unknown),Andrew J. Leishman,(unknown),Mark McHale,Robert L. Coffman,Edith M. Hessel	57
12	Dissecting the contribution of innate and antigen-specific pathways to the breach of self-tolerance observed in a murine model of arthritis 2008 ·Annals of the Rheumatic Diseases ·Mohammad B. Nickdel,Paola Conigliaro,Guido Valesini,(unknown),Robert A. Benson,R V Bundick,Andrew J. Leishman,Iain B. McInnes,James M. Brewer,Paul Garside	26
13	CD4⁺CD25⁺regulatory T cells: a therapeutic target for liver diseases 2008 ·Expert Opinion on Therapeutic Targets ·Ming‐Hua Zheng,Dian-na Gu,Martin Braddock,Andrew J. Leishman,(unknown),Jinsheng Wen,Yuewen Gong,Yongping Chen	8
14	TNF-blocking therapies: an alternative mode of action? 2005 ·Trends in Immunology ·Brian Choo‐Kang,S Hutchison,Mohammad B. Nickdel,R V Bundick,Andrew J. Leishman,James M. Brewer,Iain B. McInnes,Paul Garside	36
15	NIK-dependent RelB Activation Defines a Unique Signaling Pathway for the Development of Vα14i NKT Cells 2003 ·The Journal of Experimental Medicine ·Dirk Elewaut,(unknown),Kirsten J. L. Hammond,Hilde De Winter,Andrew J. Leishman,Stéphane Sidobre,Olga Turovskaya,Theodore I. Prigozy,Lisa Ma,Theresa A. Banks,David Lo,Carl F. Ware,Hilde Cheroutre,Mitchell Kronenberg	102
16	Precursors of Functional MHC Class I- or Class II-Restricted CD8αα+ T Cells Are Positively Selected in the Thymus by Agonist Self-Peptides 2002 ·Immunity ·Andrew J. Leishman,Laurent Gapin,Myriam Capone,Ed Palmer,H. Robson MacDonald,Mitchell Kronenberg,Hilde Cheroutre	167
17	Th1 and Th2 CD4+ T Cells Provide Help for B Cell Clonal Expansion and Antibody Synthesis in a Similar Manner In Vivo 2000 ·The Journal of Immunology ·Karen Smith,(unknown),Elaine Thomas,Andrew J. Leishman,(unknown),Damo Xu,Foo Y. Liew,Paul Garside	149
18	Induction of Oral Tolerance in the Primed Immune System: Influence of Antigen Persistence and Adjuvant Form 2000 ·Cellular Immunology ·Andrew J. Leishman,Paul Garside,Allan McI. Mowat	34
19	Normal Induction of Oral Tolerance in the Absence of a Functional IL-12-Dependent IFN-γ Signaling Pathway 1999 ·The Journal of Immunology ·Allan McI. Mowat,Margaret Steel,Andrew J. Leishman,Paul Garside	29
20	Immunological Consequences of Intervention in Established Immune Responses by Feeding Protein Antigens 1998 ·Cellular Immunology ·Andrew J. Leishman,Paul Garside,Allan McI. Mowat	24

About Andrew J. Leishman

Andrew J. Leishman is a scholar working on Immunology, Oncology and Emergency Medical Services, having authored 34 papers that have together received 1.3k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (16 papers), Immune Response and Inflammation (11 papers) and Immunotherapy and Immune Responses (9 papers). The work is most often cited by research in Immunology (966 citations), Immunology and Allergy (63 citations) and Oncology (265 citations). Andrew J. Leishman has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include Paul Garside, Hilde Cheroutre, Mitchell Kronenberg, Allan McI. Mowat, H. Robson MacDonald, Laurent Gapin, Myriam Capone, Ed Palmer, Hsiu‐Ching Chang and Antoine Attinger. Their work appears in journals such as Science, Journal of Clinical Investigation and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact